Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SYDNEY, Australia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- We refer to shareholder approval granted at the Company’s Annual General Meeting held on 17 November 2017 to change the name of the Company from...
-
SYDNEY, Australia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 2604275 entitled “Use of Recombinant LAG-3...
-
SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep...
-
SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND)...
-
SYDNEY, Australia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial...
-
SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer,...
-
SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer,...
-
SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company’s...
-
SYDNEY, Australia, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of Japanese patent no. 6177735 entitled “Cytotoxic...
-
SYDNEY, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 6169734 entitled “Use of Recombinant...